Salby Alon M, Skalicky Simon E
Department of Ophthalmology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Glaucoma Unit, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia.
Clin Ophthalmol. 2020 Mar 31;14:985-993. doi: 10.2147/OPTH.S241628. eCollection 2020.
This retrospective audit aimed to evaluate the impact of combined iStent (iSI) and phacoemulsification on medication number in Australians with open-angle glaucoma. Secondary outcomes included intraocular pressure (IOP), best-corrected visual acuity, refraction and visual fields.
Patients with glaucoma that received combined iSI and phacoemulsification by the same surgeon between 1 February 2016 and 1 February 2018 were audited for postoperative medication number, pressures after 1 day, 1 week, 4 weeks and 6, 12, 18 and 24 months, visual acuity, refraction and visual fields. These parameters were compared to baseline levels and with those from a separate cohort of patients without glaucoma that received standalone phacoemulsification.
Forty-one patients (63 eyes) received the combined procedure. Thirty-four patients (59 eyes) received standalone phacoemulsification. Four weeks after receiving combined iSI and phacoemulsification the mean medication number was significantly reduced by 1.3 (p < 0.001) for those on medication at baseline and by 0.5 (p = 0.002) overall. Mean IOP was significantly reduced from baseline after 6 months (-16%; p = 0.012; n = 35) and 12 months (-29%; p = 0.004; n = 16). Patients receiving standalone phacoemulsification had short-term reductions in IOP at 4 weeks (-8%; p < 0.001; n = 57) and 6 months (-16%; p < 0.001; n = 32). These patients without glaucoma had lower pressures overall compared to those with glaucoma that received the combined procedure (p = 0.019). There were no differences in final visual acuity or refractive outcomes between groups.
This audit suggests that iSI and phacoemulsification are at least as effective in controlling IOP as medical therapy. It may have an important role in reducing the medication burden in Australians with cataract and glaucoma. This study is one of the first to confirm refractive stability in concomitant iSI and phacoemulsification.
这项回顾性审计旨在评估iStent(iSI)与超声乳化术联合应用对澳大利亚开角型青光眼患者用药数量的影响。次要结果包括眼压(IOP)、最佳矫正视力、屈光和视野。
对2016年2月1日至2018年2月1日期间由同一位外科医生进行iSI与超声乳化术联合治疗的青光眼患者的术后用药数量、术后1天、1周、4周以及6、12、18和24个月后的眼压、视力、屈光和视野进行审计。将这些参数与基线水平以及另一组接受单纯超声乳化术的非青光眼患者的参数进行比较。
41例患者(63只眼)接受了联合手术。34例患者(59只眼)接受了单纯超声乳化术。在接受iSI与超声乳化术联合治疗后4周,基线时正在用药的患者平均用药数量显著减少1.3(p < 0.001),总体平均用药数量减少0.5(p = 0.002)。6个月(-16%;p = 0.012;n = 35)和12个月(-29%;p = 0.004;n = 16)后,平均眼压较基线显著降低。接受单纯超声乳化术的患者在4周(-8%;p < 0.001;n = 57)和6个月(-16%;p < 0.001;n = 32)时眼压有短期降低。这些非青光眼患者的总体眼压低于接受联合手术的青光眼患者(p = 0.019)。两组之间最终视力或屈光结果无差异。
这项审计表明,iSI与超声乳化术在控制眼压方面至少与药物治疗一样有效。它在减轻澳大利亚白内障和青光眼患者的用药负担方面可能具有重要作用。本研究是首批证实iSI与超声乳化术联合应用时屈光稳定性的研究之一。